ALPS Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $515K | Sell |
667
-150
| -18% | -$115K | ﹤0.01% | 758 |
|
|
2025
Q4 | $631K | Sell |
817
-1
| -0.1% | -$679 | ﹤0.01% | 669 |
|
|
2025
Q3 | $460K | Buy |
818
+282
| +53% | +$159K | ﹤0.01% | 754 |
|
|
2025
Q2 | $281K | Buy |
536
+6
| +1% | +$3.35K | ﹤0.01% | 950 |
|
|
2025
Q1 | $336K | Buy |
530
+220
| +71% | +$151K | ﹤0.01% | 849 |
|
|
2024
Q4 | $221K | Hold |
310
| – | – | ﹤0.01% | 967 |
|
|
2024
Q3 | $326K | Buy |
+310
| New | +$345K | ﹤0.01% | 929 |
|
|
2024
Q1 | – | Sell |
-390
| Closed | -$343K | – | 1050 |
|
|
2023
Q4 | $343K | Sell |
390
-10
| -3% | -$8.23K | ﹤0.01% | 781 |
|
|
2023
Q3 | $329K | Sell |
400
-25
| -6% | -$19.6K | ﹤0.01% | 762 |
|
|
2023
Q2 | $305K | Buy |
425
+5
| +1% | +$3.85K | ﹤0.01% | 862 |
|
|
2023
Q1 | $345K | Buy |
+420
| New | +$317K | ﹤0.01% | 692 |
|
|
2022
Q3 | – | Sell |
-523
| Closed | -$309K | – | 1167 |
|
|
2022
Q2 | $309K | Sell |
523
-5
| -0.9% | -$3.25K | ﹤0.01% | 781 |
|
|
2022
Q1 | $369K | Sell |
528
-42
| -7% | -$26.6K | ﹤0.01% | 565 |
|
|
2021
Q4 | $360K | Buy |
570
+7
| +1% | +$4.3K | ﹤0.01% | 760 |
|
|
2021
Q3 | $341K | Buy |
+563
| New | +$350K | ﹤0.01% | 787 |
|
|
2021
Q1 | – | Sell |
-456
| Closed | -$220K | – | 942 |
|
|
2020
Q4 | $220K | Sell |
456
-1,109
| -71% | -$599K | ﹤0.01% | 829 |
|
|
2020
Q3 | $876K | Buy |
1,565
+14
| +0.9% | +$8.49K | 0.01% | 364 |
|
|
2020
Q2 | $967K | Buy |
1,551
+1,096
| +241% | +$622K | 0.01% | 319 |
|
|
2020
Q1 | $222K | Buy |
+455
| New | +$188K | ﹤0.01% | 703 |
|
|
2019
Q3 | – | Sell |
-916
| Closed | -$287K | – | 964 |
|
|
2019
Q2 | $287K | Sell |
916
-48
| -5% | -$16K | ﹤0.01% | 848 |
|
|
2019
Q1 | $396K | Sell |
964
-225
| -19% | -$92.7K | ﹤0.01% | 732 |
|
|
2018
Q4 | $444K | Sell |
1,189
-50
| -4% | -$18.3K | ﹤0.01% | 523 |
|
|
2018
Q3 | $501K | Sell |
1,239
-120
| -9% | -$45.7K | ﹤0.01% | 606 |
|
|
2018
Q2 | $469K | Sell |
1,359
-299
| -18% | -$93.5K | ﹤0.01% | 650 |
|
|
2018
Q1 | $571K | Buy |
1,658
+308
| +23% | +$107K | ﹤0.01% | 440 |
|
|
2017
Q4 | $508K | Buy |
1,350
+293
| +28% | +$119K | ﹤0.01% | 540 |
|
|
2017
Q3 | $473K | Sell |
1,057
-350
| -25% | -$167K | ﹤0.01% | 617 |
|
|
2017
Q2 | $691K | Buy |
1,407
+135
| +11% | +$59.1K | ﹤0.01% | 296 |
|
|
2017
Q1 | $493K | Buy |
1,272
+186
| +17% | +$68.9K | ﹤0.01% | 452 |
|
|
2016
Q4 | $399K | Buy |
1,086
+10
| +0.9% | +$3.8K | ﹤0.01% | 592 |
|
|
2016
Q3 | $433K | Sell |
1,076
-5
| -0.5% | -$2.01K | ﹤0.01% | 393 |
|
|
2016
Q2 | $378K | Sell |
1,081
-80
| -7% | -$30.8K | ﹤0.01% | 508 |
|
|
2016
Q1 | $418K | Buy |
+1,161
| New | +$478K | ﹤0.01% | 536 |
|
|
2015
Q1 | – | Sell |
-1,449
| Closed | -$594K | – | 747 |
|
|
2014
Q4 | $594K | Sell |
1,449
-198
| -12% | -$77.9K | ﹤0.01% | 283 |
|
|
2014
Q3 | $594K | Sell |
1,647
-180
| -10% | -$60.3K | ﹤0.01% | 298 |
|
|
2014
Q2 | $516K | Buy |
1,827
+48
| +3% | +$14.2K | ﹤0.01% | 516 |
|
|
2014
Q1 | $534K | Buy |
1,779
+199
| +13% | +$61.3K | 0.01% | 531 |
|
|
2013
Q4 | $456K | Buy |
1,580
+770
| +95% | +$221K | ﹤0.01% | 471 |
|
|
2013
Q3 | $253K | Buy |
+810
| New | +$213K | ﹤0.01% | 370 |
|
Other funds holding REGN
VCM
N
ALPS Advisors's REGN Position: Q1 2026 in Review
ALPS Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $115K and leaving 667 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #758.
ALPS Advisors first reported a position in REGN in Q3 2013 and has held it in 39 quarters since. The position peaked at $967K in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- ALPS Advisors held 667 shares of Regeneron Pharmaceuticals worth $515K as of Q1 2026.
- ALPS Advisors sold 150 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $115K.
- Regeneron Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #758 holding.
- ALPS Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 39 quarters since.
- ALPS Advisors's Regeneron Pharmaceuticals position peaked at $967K in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.